Nancy Denyes
CIK: 0001640869
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
aTYR PHARMA INC
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Feb 4, 2026ATYR
aTYR PHARMA INC
Sale(S)Direct1.1K shares at avg. $0.98$1K - Feb 3, 2026ATYR
aTYR PHARMA INC
Exercise(M)Direct2.7K shares- - Jan 9, 2026ATYR
aTYR PHARMA INC
Award(A)DirectEmployee Stock Options (right to buy)
412.5K shares- - Feb 4, 2025ATYR
aTYR PHARMA INC
Sale(S)Direct899 shares at avg. $3.78$3K - Feb 3, 2025ATYR
aTYR PHARMA INC
Exercise(M)Direct2.7K shares- - Jan 8, 2025ATYR
aTYR PHARMA INC
Award(A)DirectEmployee Stock Option (right to buy)
275K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 4, 2026 | ATYR aTYR PHARMA INC | Sale(S) | 1,118 | $0.98 | $1,091 | Direct |
| Feb 3, 2026 | ATYR aTYR PHARMA INC | Exercise(M) | 2,687 | - | $0 | Direct |
| Jan 9, 2026 | ATYR aTYR PHARMA INC | Award(A) Employee Stock Options (right to buy) | 412,500 | - | - | Direct |
| Feb 4, 2025 | ATYR aTYR PHARMA INC | Sale(S) | 899 | $3.78 | $3,398 | Direct |
| Feb 3, 2025 | ATYR aTYR PHARMA INC | Exercise(M) | 2,687 | - | - | Direct |
| Jan 8, 2025 | ATYR aTYR PHARMA INC | Award(A) Employee Stock Option (right to buy) | 275,000 | - | - | Direct |
1-6 of 6 transactions
About DENYES NANCY
DENYES NANCY (SEC CIK 0001640869) files insider reports with the SEC as General Counsel of aTYR PHARMA INC (ATYR).
Signal8 holds 4 ownership filings by DENYES NANCY, all Form 4s, filed between Jan 10, 2025 and Feb 4, 2026. Those filings report 6 transactions, from Jan 8, 2025 to Feb 4, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on DENYES NANCY's filings is in SAN DIEGO, CA.
Recent filings by DENYES NANCY
- Feb 4, 2026: Open-market sale of ATYR shares (Form 4, code S).
- Feb 3, 2026: Option exercise of ATYR shares (Form 4, code M).
- Jan 9, 2026: Grant or award of ATYR derivative securities (Form 4, code A).
- Feb 4, 2025: Open-market sale of ATYR shares (Form 4, code S).
- Feb 3, 2025: Option exercise of ATYR shares (Form 4, code M).
Other insiders filing for aTYR PHARMA INC (ATYR)
- Yaras Brandon, Chief Financial Officer
- SCHIMMEL PAUL, Director
- Coughlin Timothy, Director
- BENEVICH ERIC, Director
- Gross Jane A, Director
- Lucas Svetlana, Director